Seattle, WA – [ Business Wire ] – The Max Foundation (“Max”), an international health organization dedicated to serving cancer patients, and Tanner Pharma Group (“Tanner”), a global pharma services company specializing in access to critical medication, are committed partners in bringing thousands of patients around the globe daily access to cancer treatment. Within The Max Foundation’s patient-centered model, Max Access Solutions (MAS), Tanner plays a critical role by leading quality, regulatory and logistics to ensuring donated oncology products get to the right patient in the right place at the right time. MAS programs currently deliver 1,000,000 daily doses per Quarter.
Among the dozens of countries The Max Foundation supports, many are located in Africa. To raise awareness and funds for increased treatment access on the continent, Max has created a 2018 campaign known as the Max Global Experience: Uganda.
This campaign is focused on the proverbial “last mile,” which refers to the unseen efforts of patients and caregivers to make treatment truly accessible. All too often, patients must travel great distances to attend medical appointments and receive their medication. Max works to bridge these gaps by broadening its geographic reach, working with local patient groups, advocating to governments, and partnering with distribution experts like Tanner. Tanner has proudly offered to be the title sponsor for the Max Global Experience: Uganda and their parent company, Bourne Partners, will match up to $10,000 in funds raised.
“As we work to find solutions for patients in need, we feel fortunate to partner with a trusted Managed Access Program provider like Tanner Pharma Group ,” said Pat Garcia-Gonzalez, CEO and co-founder of The Max Foundation. “We are strongly aligned in our values around the importance of access to cancer treatment for people around the world. As a result, we have forged a successful partnership in our Max Access Solution model which provides life-saving medication to patients in more than 70 countries. We look forward to growing our programs with Tanner and improving the lives of more cancer patients in under-resourced countries.”
“We are proud of our affiliation with The Max Foundation and the support we provide for their innovative, globally recognized programs,” added Banks Bourne, Founder & Chairman of Tanner Pharma Group and CEO of Bourne Partners. “Working with Pat and her team is deeply rewarding. Their hard work has led to monumental impact at the patient level.”
In 2017, Mr. Bourne attended another Max Global Experience, this time climbing Mt. Kinabalu in Malaysia. Banks recalls, “Seeing their work in Asia last summer and looking ahead to the upcoming trip to Africa has been inspirational and makes Tanner’s mission even more meaningful.”
Tanner Pharma Group partners with biopharmaceutical companies and NGOs to provide turn-key solutions that facilitate access to medicines around the world. Every member of the Tanner Team believes that access to medicines should have no borders and we measure our value as a company based on the lives we improve. For more information, please visit www.tannerpharma.com.
Erin Schwartz, The Max Foundation
eschwartz@themaxfoundation.org
+1-425-778-8660
Lindsey Stevens, Tanner Pharma Group
lstevens@tannerpharma.com
+1-704-552-8407
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
The program, Max GPS, will support cancer patients from medically underserved and underrepresented communities. SEATTLE – July 19, 2024 – The Max Foundation (Max), a global nonprofit organization that aims to accelerate health equity by delivering medication, technology, and supportive services to patients worldwide, is launching Max GPS, its new patient navigation program in the….
Max to immediately begin process to provide humanitarian access for Fabhalta® (iptacopan) in collaboration with its network of partner hematologists across 53 countries People living with the rare blood disease in low-middle income countries require frequent blood transfusions, experience debilitating symptoms of fatigue and without treatment may progress to more serious life-threatening diseases The Max….
Max adds three new members to the Board of Directors, increasing the seats from eight to 11 In addition, Max has added 10 new team members in 2024 to support growing patient reach, collaboration with partners, and new disease areas This expansion will ensure Max can meet its strategic goals, including treating more patients, amplifying….
